STAT+: Humana projects sharply lower earnings as Medicare membership surges
Stat News • 2/11/2026
Summary
Humana projects sharply lower earnings due to an expected increase in spending on medical care for some new members. The company anticipates generating relatively less revenue as Medicare membership surges.
Advertisement
Lindy Score Breakdown (V4.2)
52d
Age
1
Sources
from cluster
1245
Hours Since Seen
Final Score0/100
CategoryAntiLindy
StatusArchived
Recency Multiplier0% (0.5^1245/48)
Hero EligibleNo
Score is 0 because recency decay (0.5^1245/48 = 0.000000) reduced it below 0.5
Score BreakdownRisk 50
Source Reputation: Low-trust source (4/20 pts)
Consensus: Single source - no independent confirmation yet
Age: 51 days - proven survivor
Stories gain Lindy status through source reputation, network consensus, and time survival.
Breaking Similar stories
STAT+: Medicare Advantage plans win extra $18.6 billion as feds cut star ratings measures
Stat News • 1 day ago
STAT+: Trump administration prepares 100% tariffs on some imported drugs
Stat News • 2 days ago
STAT+: NIH would get $5 billion cut under Trump’s 2027 budget, but Congress unlikely to go along
Stat News • Today
STAT reporter goes up against radiologists to spot deepfake X-rays
Stat News • 2 days ago
STAT+: Biotech investors’ plea to Trump, and a busy M&A week
Stat News • 1 day ago
STAT+: How health care could gum up Trump’s reconciliation push
Stat News • 2 days ago
STAT+: ‘Takeover Tuesday’ saves biotech’s quarter
Stat News • 2 days ago
STAT+: Makary marks one year at FDA with focus on achievements in speech to staff
Stat News • 2 days ago
STAT+: Large AI scribe study finds modest time savings, inconsistent use
Stat News • 2 days ago
STAT+: Lilly’s obesity pill enters the oral GLP-1 game, Novo responds
Stat News • 2 days ago
Anti-Lindy Similar stories
STAT+: Pharmalittle: We’re reading about Trump pushing drug pricing policy, Chinese biotech licensing, and more
Stat News • 5 days ago
STAT+: FDA approves Denali Therapeutics drug for Hunter syndrome
Stat News • 1 week ago
STAT+: Pharmalittle: We’re reading about a Merck acquisition, the rise of former Loxo execs at Lilly, and more
Stat News • 1 week ago
STAT+: Pharmalittle: We’re reading about an FDA OK for a rare disease drug, a grilling of the PTO chief, and more
Stat News • 1 week ago